Corvus Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRVS research report →
About the company
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers.
- CEO
- Richard A. Miller
- IPO
- 2016
- Employees
- 31
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $1.28B
- P/E
- -27.69
- P/S
- 0.00
- P/B
- 5.69
- EV/EBITDA
- -29.37
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.92%
- ROIC
- -19.84%
- Revenue
- $0 · 0.00%
- Net Income
- $-15,283,000 · 75.47%
- EPS
- $-0.19 · 81.37%
- Op Income
- $-42,971,000
- FCF YoY
- -29.68%
- 52W High
- $26.95
- 52W Low
- $3.79
- 50D MA
- $13.53
- 200D MA
- $12.20
- Beta
- 0.82
- Avg Volume
- 1.51M
Get TickerSpark's AI analysis on CRVS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 11, 26 | Moore David Scott | buy | 21,700 |
| Jun 11, 26 | Moore David Scott | other | 15,000 |
| Jun 11, 26 | CLARK IAN T | other | 15,000 |
| Jun 11, 26 | Grais Linda | other | 15,000 |
| Jun 11, 26 | Thompson Peter A. | other | 15,000 |
| Jun 11, 26 | van den Broek Richard | other | 15,000 |
| May 18, 26 | MILLER RICHARD A MD | buy | 1,932 |
| May 18, 26 | MILLER RICHARD A MD | buy | 5,000 |
| Apr 23, 26 | Chan Andrew C. | other | 30,000 |
| Apr 23, 26 | Chan Andrew C. | other | 0 |
Our CRVS coverage
Recent articles, reports, and earnings notes.
No research on CRVS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRVS report →Similar companies
Peers in the same neighborhood.